Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**. The round included investment from Porton Capital, Oxford Technology Management, New Hill (Boston, USA), Midven, the Rainbow Seed Fund, Finance Wales and private investors...
More...
More...